Intimation of allotment 375 Equity shares under Rossari Employee Stock Option Plan -2019.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rossari Biotech's Board, at its meeting on July 19, 2025, approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Consolidated revenue from operations rose to Rs. 5,437.16 million from Rs. 4,896.50 million in Q1 FY25, while profit after tax was Rs. 335.96 million versus Rs. 348.99 million a year ago (slight dip). Standalone revenue grew strongly to Rs. 3,657.58 million from Rs. 3,007.08 million, with standalone PAT at Rs. 262.33 million (up from Rs. 243.28 million). Standalone basic EPS was Rs. 4.74 for the quarter. Separately, the Board approved allotment of 375 equity shares (face value Rs. 2) under the Rossari ESOP 2019 at an exercise price of Rs. 425 per share, raising total issued shares to 55,366,966.
The Q1 results show healthy revenue growth at both standalone and consolidated levels, though consolidated profit after tax dipped marginally year-on-year due to higher expenses. The ESOP allotment is tiny (375 shares) and has negligible dilution impact; the exercise price of Rs. 425 is well above current market levels, indicating minimal cash inflow from the scheme. No material share price impact expected from this routine disclosure.